Categories
Health

Medical hashish agency backed by Snoop Dogg begins buying and selling in London

Recording artist Snoop Dogg speaks on stage on day one of TechCrunch Disrupt SF 2015 at Pier 70 on September 21, 2015 in San Francisco, California.

Getty Images

LONDON – Oxford Cannabinoid Technologies, happily endorsed by rapper Snoop Dogg and tobacco giant Imperial Brands, launched on the London Stock Exchange on Friday.

The British company, which specializes in developing pain relieving cannabinoid drugs, grossed £ 16.5 million ($ 23.4 million) in gross proceeds on its IPO with a starting market value of just over £ 48 million ($ 69 million) .1 million USD).

The share price hovered around 5p on Friday lunchtime after opening near 8p.

Snoop Dogg, whose real name is Calvin Broadus Jr., has invested in several cannabis startups, including OCT, through his venture capital firm Casa Verde. His firm has also supported plant-based food companies like Outstanding Foods and tech names like Klarna, Robinhood, and Reddit.

Cannabinoids are naturally occurring compound chemicals found in the cannabis sativa plant and are commonly used for medicinal purposes to treat symptoms such as chronic pain.

OCT’s strategy is to develop cannabinoid drugs for the non-addictive treatment of painful conditions. CEO John Lucas told CNBC on Friday the company plans to use the proceeds of its IPO to develop four new drugs.

“The key here is getting cannabinoids into the hands of patients and the way you do that happens through the drug development process,” Lucas told CNBC’s Squawk Box Europe.

“With medical cannabis, the problem is that doctors can’t prescribe it, so we want a drug that we can get into the hands of doctors, into the hands of patients.”

In its listing announcement, OCT said its “primary market focus is on the total addressable pain market, valued at at least £ 42.5 billion through the commercialization of the first drug manufactured by OCT, currently expected in 2027.”

Categories
Business

On-line Dishonest Expenses Upend Dartmouth Medical Faculty

HANOVER, N.H. — Sirey Zhang, a first-year student at Dartmouth’s Geisel School of Medicine, was on spring break in March when he received an email from administrators accusing him of cheating.

Dartmouth had reviewed Mr. Zhang’s online activity on Canvas, its learning management system, during three remote exams, the email said. The data indicated that he had looked up course material related to one question during each test, honor code violations that could lead to expulsion, the email said.

Mr. Zhang, 22, said he had not cheated. But when the school’s student affairs office suggested he would have a better outcome if he expressed remorse and pleaded guilty, he said he felt he had little choice but to agree. Now he faces suspension and a misconduct mark on his academic record that could derail his dream of becoming a pediatrician.

“What has happened to me in the last month, despite not cheating, has resulted in one of the most terrifying, isolating experiences of my life,” said Mr. Zhang, who has filed an appeal.

He is one of 17 medical students whom Dartmouth recently accused of cheating on remote tests while in-person exams were shut down because of the coronavirus. The allegations have prompted an on-campus protest, letters of concern to school administrators from more than two dozen faculty members and complaints of unfair treatment from the student government, turning the pastoral Ivy League campus into a national battleground over escalating school surveillance during the pandemic.

At the heart of the accusations is Dartmouth’s use of the Canvas system to retroactively track student activity during remote exams without their knowledge. In the process, the medical school may have overstepped by using certain online activity data to try to pinpoint cheating, leading to some erroneous accusations, according to independent technology experts, a review of the software code and school documents obtained by The New York Times.

Dartmouth’s drive to root out cheating provides a sobering case study of how the coronavirus has accelerated colleges’ reliance on technology, normalizing student tracking in ways that are likely to endure after the pandemic.

While universities have long used anti-plagiarism software and other anti-cheating apps, the pandemic has pushed hundreds of schools that switched to remote learning to embrace more invasive tools. Over the last year, many have required students to download software that can take over their computers during remote exams or use webcams to monitor their eye movements for possibly suspicious activity, even as technology experts have warned that such tools can be invasive, insecure, unfair and inaccurate.

Some universities are now facing a backlash over the technology. A few, including the University of Illinois at Urbana-Champaign, recently said they would cease using the exam-monitoring tools.

“These kinds of technical solutions to academic misconduct seem like a magic bullet,” said Shaanan Cohney, a cybersecurity lecturer at the University of Melbourne who researches remote learning software. But “universities which lack some of the structure or the expertise to understand these issues on a deeper level end up running into really significant trouble.”

At Dartmouth, the use of Canvas in the cheating investigation was unusual because the software was not designed as a forensic tool. Instead, professors post assignments on it and students submit their homework through it.

That has raised questions about Dartmouth’s methodology. While some students may have cheated, technology experts said, it would be difficult for a disciplinary committee to distinguish cheating from noncheating based on the data snapshots that Dartmouth provided to accused students. And in an analysis of the Canvas software code, The Times found instances in which the system automatically generated activity data even when no one was using a device.

“If other schools follow the precedent that Dartmouth is setting here, any student can be accused based on the flimsiest technical evidence,” said Cooper Quintin, senior staff technologist at the Electronic Frontier Foundation, a digital rights organization, who analyzed Dartmouth’s methodology.

Seven of the 17 accused students have had their cases dismissed. In at least one of those cases, administrators said, “automated Canvas processes are likely to have created the data that was seen rather than deliberate activity by the user,” according to a school email that students made public.

The 10 others have been expelled, suspended or received course failures and unprofessional-conduct marks on their records that could curtail their medical careers. Nine pleaded guilty, including Mr. Zhang, according to school documents; some have filed appeals.

Some accused students said Dartmouth had hamstrung their ability to defend themselves. They said they had less than 48 hours to respond to the charges, were not provided complete data logs for the exams, were advised to plead guilty though they denied cheating or were given just two minutes to make their case in online hearings, according to six of the students and a review of documents.

Five of the students declined to be named for fear of reprisals by Dartmouth.

Duane A. Compton, the dean of the Geisel School, said in an interview that its methods for identifying possible cheating cases were fair and valid. Administrators investigated carefully, he said, and provided accused students with all the data on which the cheating charges were based. He denied that the student affairs office had advised those who said they had not cheated to plead guilty.

Dr. Compton acknowledged that the investigation had caused distress on campus. But he said Geisel, founded in 1797 and one of the nation’s oldest medical schools, was obligated to hold its students accountable.

“We take academic integrity very seriously,” he said. “We wouldn’t want people to be able to be eligible for a medical license without really having the appropriate training.”

Updated 

May 8, 2021, 5:12 p.m. ET

Instructure, the company that owns Canvas, did not return requests for comment.

In January, a faculty member reported possible cheating during remote exams, Dr. Compton said. Geisel opened an investigation.

To hinder online cheating, Geisel requires students to turn on ExamSoft — a separate tool that prevents them from looking up study materials during tests — on the laptop or tablet on which they take exams. The school also requires students to keep a backup device nearby. The faculty member’s report made administrators concerned that some students may have used their backup device to look at course material on Canvas while taking tests on their primary device.

Geisel’s Committee on Student Performance and Conduct, a faculty group with student members that investigates academic integrity cases, then asked the school’s technology staff to audit Canvas activity during 18 remote exams that all first- and second-year students had taken during the academic year. The review looked at more than 3,000 exams since last fall.

The tech staff then developed a system to recognize online activity patterns that might signal cheating, said Sean McNamara, Dartmouth’s senior director of information security. The pattern typically showed activity on a Canvas course home page — on, say, neurology — during an exam followed by activity on a Canvas study page, like a practice quiz, related to the test question.

“You see that pattern of essentially a human reading the content and selecting where they’re going on the page,” Mr. McNamara said. “The data is very clear in describing that behavior.”

The audit identified 38 potential cheating cases. But the committee quickly eliminated some of those because one professor had directed students to use Canvas, Dr. Compton said.

In emails sent in mid-March, the committee told the 17 accused students that an analysis showed they had been active on relevant Canvas pages during one or more exams. The emails contained spreadsheets with the exam’s name, the test question number, time stamps and the names of Canvas pages that showed online activity.

Almost immediately, questions emerged over whether the committee had mistaken automated activity on Canvas for human activity, based on a limited subset of exam data.

Geisel students said they often had dozens of course pages open on Canvas, which they rarely logged out of. Those pages can automatically generate activity data even when no one is looking at them, according to The Times’s analysis and technology experts.

School officials said that their analysis, which they hired a legal consulting firm to validate, discounted automated activity and that accused students had been given all necessary data in their cases.

Class Disrupted

Updated May 5, 2021

The latest on how the pandemic is reshaping education.

But at least two students told the committee in March that the audit had misinterpreted automated Canvas activity as human cheating. The committee dismissed the charges against them.

In another case, a professor notified the committee that the Canvas pages used as evidence contained no information related to the exam questions his student was accused of cheating on, according to an analysis submitted to the committee. The student has appealed.

The committee has also not provided students with the wording of the exam questions they were accused of cheating on, complete Canvas activity logs for the exams, the amount of time spent on each Canvas page and data on whether the system flagged their page activity as automated or user-initiated, according to documents.

Dartmouth declined to comment on the data issues, citing the appeals.

Mr. Quintin of the Electronic Frontier Foundation compared Dartmouth’s methods to accusing someone of stealing a piece of fruit in a grocery store by presenting a snapshot of that person touching an orange, but not releasing video footage showing whether the person later put back the orange, bought it or pocketed it without paying.

Dr. Compton said the committee’s dismissal of cases over time validated its methodology.

The fact that we had a large number of students and we were very deliberate about eliminating a large, large fraction or majority of those students from consideration,” he said, “I think actually makes the case well for us trying to be really careful about this.”

Tensions flared in early April when an anonymous student account on Instagram posted about the cheating charges. Soon after, Dartmouth issued a social media policy warning that students’ anonymous posts “may still be traced back” to them.

Around the same time, Geisel administrators held a virtual forum and were barraged with questions about the investigation. The conduct review committee then issued decisions in 10 of the cases, telling several students that they would be expelled, suspending others and requiring some to retake courses or repeat a year of school at a cost of nearly $70,000.

Many on campus were outraged. On April 21, dozens of students in white lab coats gathered in the rain in front of Dr. Compton’s office to protest. Some held signs that said “BELIEVE YOUR STUDENTS” and “DUE PROCESS FOR ALL” in indigo letters, which dissolved in the rain into blue splotches.

Several students said they were now so afraid of being unfairly targeted in a data-mining dragnet that they had pushed the medical school to offer in-person exams with human proctors. Others said they had advised prospective medical students against coming to Dartmouth.

“Some students have built their whole lives around medical school and now they’re being thrown out like they’re worthless,” said Meredith Ryan, a fourth-year medical student not connected to the investigation.

That same day, more than two dozen members of Dartmouth’s faculty wrote a letter to Dr. Compton saying that the cheating inquiry had created “deep mistrust” on campus and that the school should “make amends with the students falsely accused.”

In an email to students and faculty a week later, Dr. Compton apologized that Geisel’s handling of the cases had “added to the already high levels of stress and alienation” of the pandemic and said the school was working to improve its procedures.

The medical school has already made one change that could reduce the risk of false cheating allegations. For remote exams, new guidelines said, students are now “expected to log out of Canvas on all devices prior to testing.”

Mr. Zhang, the first-year student, said the investigation had shaken his faith in an institution he loves. He had decided to become a doctor, he said, to address disparities in health care access after he won a fellowship as a Dartmouth undergraduate to study medicine in Tanzania.

Mr. Zhang said he felt compelled to speak publicly to help reform a process he found traumatizing.

“I’m terrified,” he said. “But if me speaking up means that there’s at least one student in the future who doesn’t have to feel the way that I did, then it’s all worthwhile.”

Categories
Health

Medicare must OK rule giving seniors entry to FDA-approved medical units

Mina De La O | Digital vision | Getty Images

Dr. Anand Shah is an oncologist and former FDA Assistant Commissioner and former Chief Medical Officer of the Center for Medicare & Medicaid Innovation. He is also an advisor to Morgan Stanley.

Navigating public and commercial health insurance to cover innovative medical products can be a never-ending cycle of bureaucracy.

Medical technologies classified as “safe and effective” by the Food and Drug Administration – the global gold standard for regulating drugs and devices – are not always covered by the Centers for Medicare & Medicaid Services, adding the added hurdle for companies Proof of their requirements must be met Product is “reasonable and necessary”.

Unlike medications, which are typically covered by CMS immediately after FDA approval, seniors can only access many FDA cleared or approved medical diagnoses and devices if they can participate in a CMS approved clinical trial. These studies can take years – additional data and a lengthy regulatory process to determine coverage criteria – and in the meantime sustain potentially life-saving medical interventions from Medicare beneficiaries.

A new policy, due to go into effect in mid-March, would have allowed seniors and their doctors to decide whether or not they needed these devices. However, it was postponed along with other pending regulations when the Biden Administration took office. The proposed Medicare Innovative Technologies Coverage Policy, postponed until May 15 for regulatory review, leverages existing FDA legal expertise under the Breakthrough Devices program to identify a limited number of promising medical technologies, and offers these products a short Medicare warranty. granted on the day of FDA approval.

The proposed policy would be a critical step forward for Medicare beneficiaries to make informed decisions about their care.

Currently, the FDA has approved, authorized, or cleared at least 26 breakthrough diagnoses and devices. These medical products include in vitro diagnostic and imaging platforms for implants and wearable devices that cover a range of diseases, including Ebola, traumatic brain injury, severe emphysema, and heart disease.

As an oncologist who helped develop this medical device policy at CMS, I have looked after many patients who have not had access to state-of-the-art tests such as next-generation DNA sequencing as part of a cancer screening because Medicare does not allow them. The same product can often be obtained by the patient through a commercial insurance policy, which many do not get under the Medicare program after aging. As a last resort, the patient has no choice but to pay out of pocket.

Seniors deserve access to FDA-named breakthrough medical devices – narrowly defined by Congress to include the most promising new technologies, such as those that can treat life-threatening or irreversibly debilitating conditions – once the FDA deems them safe and effective.

It is important that the proposed rule maintain the same high standards required by both the FDA and the CMS. In addition, the existing FDA requirements for post-market surveillance will be maintained. This policy bridges the void for patients who would otherwise not have access to the latest FDA authorized technology while waiting for CMS coverage. Still, it encourages researchers to continue collecting real-world evidence of health outcomes that are specific to Medicare beneficiaries.

Patient protection is maintained as MCIT uses existing procedures to restrict access to new technology when safety or efficacy concerns arise.

There is no disadvantage in approving this policy change. Seniors will have more treatment options, and medical technology innovators can work with CMS to carefully examine these patients over a four-year period, generating meaningful real-world evidence to prove that a new device is “sensible and necessary.” “Is Medicare coverage decision and potentially offers more permanent security.

This policy also encourages early investors to support innovation for the most pressing medical conditions as it creates a clear and predictable path – from investing to developing medical products to regulatory review and subsequent patient access.

If the federal government wants to incentivize investment in developing transformative medical innovations and expand choices for our seniors while promoting rigorous evidence generation, MCIT offers a clear way forward. Too many lives depend on it.

Correction: This editorial has been updated to correct the name of the agency that needs to approve the rule in the headline. It’s CMS.

Categories
Health

U.S. to present India uncooked supplies for vaccines, medical provides to struggle Covid

Medical workers in protective equipment (PPE) stand on alert in front of the Covid-19 station at Sir Ganga Ram Hospital on April 22, 2021 in New Delhi, India.

Sonu Mehta | Hindustan Times | Getty Images

WASHINGTON – The Biden government announced that it will immediately provide the raw materials needed to manufacture coronavirus vaccines in India as the country works to counter the rise in Covid-19 infections.

In the past few weeks, India has been grappling with a staggering surge in new coronavirus infections. Over the weekend, India set another world record for daily cases, bringing the country’s cumulative total to 16,960,172 cases, according to Johns Hopkins.

“Just as India sent aid to the United States because our hospitals were congested at the start of the pandemic, the United States is determined to help India in its need,” said Emily Horne, spokeswoman for the National Security Council, in a statement on Sunday.

Horne added that the United States would send raw materials to India to make the Covishield vaccine, as well as therapeutics, rapid diagnostic test kits, ventilators and protective equipment.

“The US Development Finance Corporation is funding a significant expansion of manufacturing capacity for BioE, the vaccine maker in India, so that BioE can produce at least 1 billion doses of Covid-19 vaccines by the end of 2022,” Horne wrote. The US would also send a team of public health advisors from the Center for Disease Control and USAID to India.

The announcement follows a Sunday call between Biden National Security Advisor Jake Sullivan and Indian National Security Advisor Ajit Doval. Sullivan “reiterated America’s solidarity with India, the two countries with the highest number of Covid-19 cases in the world,” read an ad on the appeal.

The US response comes after the UK, France and Germany pledged aid to India over the weekend.

On Sunday, Biden wrote on Twitter that his government was “determined to help India in its need”.

Last week, when the United States administered a new record of 200 million doses of the coronavirus vaccine, Biden told reporters that his government was looking for more ways to help internationally.

“We’re looking at what will happen to some of the vaccines we don’t use. We’re going to make sure they can be shipped safely,” Biden said on April 21.

“We don’t have enough confidence to send it abroad now. But I assume we can do it,” he added.

Categories
Health

Medical provider shares bounce in Singapore as Covid circumstances surge

Latex gloves are filled with water in a waterproof test room at a Top Glove factory in Selangor, Malaysia on December 3, 2015.

Charles Pertwee | Bloomberg | Getty Images

SINGAPORE – The stocks of several medical suppliers in Singapore rose this month, coinciding with renewed spikes in daily global Covid-19 infections.

Singapore-listed shares of Top Glove, the world’s largest manufacturer of medical gloves, are up 18.4% since March 31st. The company’s shares in Malaysia, where it is based, rose 24.3% over the same period.

Other stocks of Singapore medical suppliers that rose sharply this month include:

These stocks all outperformed the Straits Times benchmark index, which rose 0.7% between March 31 and Thursday. Geoff Howie, market strategist on the Singapore Exchange, told CNBC in an email that they were also among the top 100 most traded stocks in the Singapore market this year.

Howie said a revival in daily confirmed Covid-19 cases and vaccine safety concerns may have sparked investor interest in these stocks.

Worldwide, the 7-day moving average of the daily reported Covid cases reached a record high of more than 797,500 on Wednesday. This comes from a CNBC analysis of the data compiled by Johns Hopkins University. A major reason for the surge is an increase in daily reported cases in India, the data showed.

A moving average compensates for large spikes and drops in daily data that could be caused by the availability of tests or the frequency of reporting.

Overall, coronavirus cases reached more than 143 million cases worldwide, with around 3 million deaths on Wednesday, Hopkins data showed.

The surge in cases has also occurred as advances in Covid vaccination vary widely between rich and poor countries in what the World Health Organization has dubbed a “shocking imbalance”.

Ben May, director of global macro-research at consultancy Oxford Economics, said the recent surge in Covid infections is “clearly a major public health concern” – but it is not yet weighing on the global economy.

“Right now, it seems that the surge in cases partly reflects a growing desire by governments and individuals to get back to normal. If so, higher case numbers may not necessarily signal weaker activity ahead,” he wrote in a Monday report .

May added that the economic outlook could become more uncertain if the surge in Covid infections kills further attempts to reopen economies or leads to greater voluntary social distancing between people.

Categories
Business

Medical specialists share journey choices for vaccinated individuals

The U.S. Centers for Disease Control and Prevention has cleared vaccinated Americans for re-travel, but some vaccinated travelers remain on the fence pending summer plans.

Is it finally safe to fly? What about unvaccinated relatives or traveling with young children?

CNBC Global Traveler has asked health professionals anyone involved in the treatment or research of Covid-19 to share their travel plans for this summer. Here are their answers in their words.

Summer trips are “unlikely”

“I am unlikely to travel this summer … I am concerned that the proliferation of existing or new varieties will create the conditions for a repeat of last summer’s ebb and flow Covid-19 surge pattern. I am also concerned about vaccine hesitation … or problems with supply and access will limit our ability to achieve herd immunity in the short term. ”

“We just have to look to the recent Covid-19 surges in countries like Canada or states like Michigan to see how vaccine supply issues and the spread of variants can lead to dangerous, large-impact spikes.”

There is nothing wrong with waiting and seeing now.

Mark Cameron

Case Western Reserve University School of Medicine

“”[My kids] I’m desperate to get out of my house to a theme park this summer, but that’s just not on our cards right now. I still think there will be relatively safe travel options this summer and that there is nothing wrong with waiting. “

“Getting a full vaccination, moving our bladder with us, and maintaining the infection control measures that have made us safe so far, even when not required, would be part of the plan.”

Mark Cameron, epidemiologist and associate professor in the School of Medicine at Case Western Reserve University

Only from one house to another – by car

“I’m not going to travel this summer except to drive from where we live in New York City to our home country. Under normal circumstances, we would travel a lot, including overseas. But this year we will be spending most of our time in ours Country house as it is much easier to avoid close contact than in the city or when traveling far away. “

“If we have to get into town, we’ll do it by car. And when we get there we’ll avoid public transportation, crowded venues and indoor activities.”

This is not the time to let up….

William Haseltine

President, Access Health International

“Vaccination hasn’t changed my behavior or my summer travel plans. There are new varieties that keep popping up, and the vaccines won’t all be equally effective. Because of this, everyone in my immediate family and myself are taking the same post-vaccination precautions as before vaccination. This also includes avoiding unnecessary travel. “

“When we have to go to public places like the post office or the grocery store, we wear N95 masks and face shields, a combination that has also been shown to be effective indoors at greatly reducing the risk of infection.” “”

“If some members of our extended family have to travel over the summer, we will ask them not to visit us until two weeks after the trip – this includes the vaccinated adults and the unvaccinated children.”

“This is not the time to abandon the public health measures that can help us fight the pandemic.”

– William Haseltine, former professor at Harvard Medical School and current president of Access Health International; Author of “Variants! The Shape-Shifting Challenge of COVID-19”

Yes, but in the same region

“The family trip we’re taking this summer will be semi-local. We’re planning to get to the Jersey coast [to rent] An efficiency apartment … enjoy the hiking, beach and pool and bring our food with you. We will drive so that we can easily bring everything with us. “

Dr. Sharon Nachman said one consideration for her family’s summer travel plans to the Jersey Shore was “how easily we could get back in an emergency”.

Jon Lovette | Choice of photographer RF | Getty Images

“By bringing our own food, we reduce the need to go to areas that may be crowded or unsafe. By looking at places that offer a variety of outdoor activities, we can get the fresh air and sunshine that we missed for the meal. ” in the last few months. “

“”[My children] they were all vaccinated, but not our grandchildren. With careful planning, we plan to visit and play with them this summer. “

-DR. Sharon Nachman, director of the Pediatric Infectious Disease Department at Stony Brook Children’s Hospital

Travel plans are undecided

“I don’t have any specific plans yet. I live in California and can decide to visit local destinations with my husband for a few days driving distance, just for a break. We can also choose to fly to Hawaii. Hawaii requires pre-departure and arrival testing. My husband and I are well grown and both are now vaccinated. Part of the reason why we are pleased with the idea of ​​considering domestic travel at this point. We will definitely wear eye protection and carry travel. “

For longer flights, Dr. Supriya Narasimhan, she would consider booking a business class ticket because “the empty center seat no longer exists, airlines fly fewer flights and many are quite full”.

Nicolas Economou | NurPhoto | Getty Images

“International travel is a completely different consideration. We would like to visit the family in India in the summer because we have not seen them in the last 18 months, but India is experiencing an upswing. … People do not mask themselves reliably on and on flights Time from empty middle seats is [in the] In the past, contracting Covid while traveling is a very real risk, which is made even more complex as new variants emerge. “

“In the experience of my institution, Covid is rare after vaccination and we have not yet seen a severe case after vaccination. I trust our vaccines, but I will do my part to reduce my risk even further by masking diligently when I’m around Others. “

-DR. Supriya Narasimhan, chief infectious disease at Santa Clara Valley Medical Center

Definitely when traveling, but only domestically

“My wife and I will be traveling by plane to visit relatives on the east coast. We will wear masks and be aware of the social distance throughout the terminal and on board.”

“Both my wife and I are fully vaccinated, as are the family we will be visiting. The introduction of the vaccine and the impact on government-mandated pre- and post-travel testing and post-travel quarantines [were] crucial to our plans. If there had still been quarantine requirements, we would have delayed the trip until they were lifted – not because of fears of infection, but only because of the practical implications. “

Dr. Charles Bailey said he plans to clean surfaces during his flight, including seat arms and controls, the tray table and “lip” of the seat pocket.

Craig Hastings | Moment | Getty Images

“If our travel plans had included infants who were not yet fully vaccinated, we would have considered the CDC recommendation for pre-travel and post-travel testing, as well as the potential impact of a post-travel quarantine period on return – school dates. It would also be a reasonable one The idea was to determine the requirements or expectations of the schools they would return to in the fall. “

-DR. Charles Bailey, Medical Director of Infection Prevention at Providence St. Joseph Hospital and Providence Mission Hospital

Going abroad this summer

“Much like many Americans, my family has plans to travel this summer. This summer, four of our family members would like to travel to Lima, Peru, and take a trip to discover the many delights of this country, including historic Machu Picchu. Seventy-two Hours before boarding the plane, we will be given a PCR Covid-19 test to protect ourselves and others. ”

“Airport and local transport are expected to be more congested than last year, so it is strongly recommended that all travelers be vaccinated. As healthcare providers, my wife and I are both fully vaccinated, and ours [adult] Children are vaccinated prior to our travel activities. “

“It is important before you make travel arrangements to any destination you have studied … the rate of infectivity … should be less than 5%.”

“Data can change quickly and it is important to follow current guidelines and recommendations from local authorities.”

-DR. Ramon Tallaj, chairman of New York’s Somos Community Care

Editor’s Note: Peru is currently under a Level 4 Covid travel advisory from the CDC. According to the CDC website, travelers should avoid traveling to Peru.

Categories
Politics

Brian Sicknick died of pure causes after Capitol riot, medical expert guidelines

A U.S. Capitol officer holds a program in which people honor the remains of U.S. Capitol officer Brian Sicknick, who lays in the rotunda of the U.S. Capitol building in Washington, DC on February 3, 2021, pay their respects.

Demetrius Freeman | AFP | Getty Images

Police officer Brian Sicknick suffered strokes and died a day after facing a seditious crowd of supporters of former President Donald Trump during the invasion of the U.S. Capitol on Jan. 6.

The verdict, released Monday by Chief Medical Officer Francisco Diaz’s office, could make prosecutions difficult for two men accused last month of using a chemical spray to attack Sicknick.

The bureau found that Sicknick, 42, was “sprayed with a chemical outside the US Capitol” during the invasion around 2:20 pm

At around 10 p.m. that night, Sicknick collapsed in the Capitol and was ruled to be hospitalized. He died there at 9:30 p.m. the following evening.

Sicknick’s official cause of death was “acute brainstem and cerebellar infarction due to acute thrombosis of the basilar artery,” said Diaz’s office.

The mode of death – the circumstances surrounding Sicknick’s death – was “natural”. This term is used when death is caused solely by illness and is judged not to be accelerated by injury.

But, in an interview with the Washington Post, Diaz noted Sicknick’s role in confronting the rioters hours before his collapse, saying, “Everything that happened played a role in his condition.”

Even so, Diaz told the newspaper that Sicknick’s autopsy found no evidence that the officer was allergic to the chemical irritants that were sprayed on him during the riot.

This is the latest news. Please try again.

Categories
Health

Medical Marijuana Is Not Regulated as Most Medicines Are

Another marijuana-based drug, Nabiximole (Sativex), is available in Canada and several European countries to treat spasticity and nerve pain in patients with multiple sclerosis.

Medical cannabis is hardly a new therapeutic agent. It was widely used as a patent drug in the United States in the 19th and early 20th centuries and listed in the United States Pharmacopoeia until the passage of the Marijuana Tax Act in 1937 made it illegal.

Then a 1970 federal act made it a Schedule 1 substance that severely restricted access to marijuana for legitimate research. To make matters worse, plants like marijuana contain hundreds of active chemicals, the amounts of which can vary widely from batch to batch. Unless researchers can study purified substances in known quantities, conclusions about benefits and risks are highly unreliable.

As in Dr. Finn’s book, here are some expert conclusions about the role of medical marijuana in their respective fields:

People who use marijuana for pain relief do not reduce their dependence on opioids. In fact, Dr. Finn: “Narcotics patients who also use marijuana for pain say their pain level is still 10 on a scale of 1 to 10.” The authors of the chapter on pain, Dr. Peter R. Wilson, pain specialist at the Mayo Clinic in Rochester, Minnesota, and Dr. Sanjog Pangarkar of the Greater Los Angeles, VA Health Service concluded, “Cannabis itself does not produce analgesia and, paradoxically, it could interfere with opioid analgesia. “A 2019 study of 450 adults in the Journal of Addiction Medicine found that medical marijuana not only did not relieve pain for patients, it also increased the risk of anxiety, depression, and substance abuse.

Dr. Allen C. Bowling, a neurologist at the NeuroHealth Institute in Englewood, Colorado, noted that while marijuana has been extensively studied as a treatment for multiple sclerosis, the results of randomized clinical trials have been inconsistent. The studies overall showed some but limited effectiveness, and in one of the largest and longest studies, the placebo performed better in treating spasticity, pain, and bladder dysfunction, wrote Dr. Bowling. Most of the studies used pharmaceutical grade cannabis that is not available in pharmacies.

The study, which suggests that marijuana could reduce the risk of glaucoma, dates back to 1970. In fact, THC does lower the harmful pressure in the eye, but as Dr. Finny T. John and Jean R. Hausheer, ophthalmologists at the University of Oklahoma Health Sciences Center, wrote, “To achieve therapeutic levels of marijuana in the bloodstream for treating glaucoma, a person would have to smoke approximately six to eight times a day. At that point, the person would likely be physically and mentally incapable of performing tasks that require attention and focus, such as: B. Working and driving. The major medical eye care companies have thumbs down on marijuana as a treatment for glaucoma.

Allison Karst, a psychiatric pharmacy specialist at VA Tennessee Valley Health System who researched the benefits and risks of medical marijuana, concluded that marijuana can have “negative effects on mental health and neurological function,” including deterioration the symptoms of PTSD and bipolar disorder.

Dr. Karst also cited a study that showed that only 17 percent of edible cannabis products were accurately labeled. In an email, she wrote that the lack of regulation “creates difficulties in extrapolating available evidence to different products in the consumer market due to differences in chemical composition and purity”. She cautioned the public not to weigh “both potential benefits and risks,” which I would add a caveat to – buyers beware.

Categories
Health

Medical specialists attempt to set up ‘lengthy Covid’ analysis for sufferers with lasting signs

Critical care carers insert an endotracheal tube into a patient with coronavirus disease (COVID-19) in the intensive care unit (ICU) at Sarasota Memorial Hospital in Sarasota, Florida on February 11, 2021.

Shannon Stapleton | Reuters

Some Covid-19 patients suffer from shortness of breath, fatigue, headaches and “brain fog” for months to almost a year after their first illness. Now global medical experts are working to better diagnose and treat what they tentatively refer to as “long covid”.

Earlier this week, the World Health Organization hosted a global meeting with “patients, clinicians and other stakeholders” to improve the agency’s understanding of the post-Covid medical condition, also known as Long Covid, WHO director general Tedros Adhanom Ghebreyesus said Friday.

The meeting was the first of many to come. The goal will ultimately be to produce an “agreed clinical description” of the disease so that doctors can diagnose and treat patients effectively, he said. Given the number of people infected with the virus worldwide – nearly 108 million people as of Friday – Tedros warned that many of these persistent symptoms are likely to appear.

“This disease affects patients with severe and mild Covid-19,” Tedros said during a press conference at the agency’s headquarters in Geneva. “Part of the challenge is that long-term Covid patients can have a range of different symptoms that can be persistent or come and go.”

Limited dates

So far, there have been a limited number of studies that will determine what symptoms are most common and how long they might last. The main focus was on people with a serious or fatal illness, not people who have recovered but still report persistent side effects, sometimes referred to as “long distance riders”.

Most Covid patients are believed to recover only weeks after their initial diagnosis, but some have symptoms for six months or even almost a year, medical experts say.

One of the largest global studies on Long Covid, published in early January, found that many people who have persistent illness after infection cannot work full-time six months later. The study, published on MedRxiv and not peer reviewed, interviewed more than 3,700 people, ages 18 to 80, from 56 countries to identify symptoms.

The most common symptoms after six months were fatigue, post-exercise fatigue, and cognitive dysfunction, sometimes called brain fog.

Is that unique to Covid-19?

“We really don’t know what is causing these symptoms. That is a focus of research right now,” said Dr. Allison Navis, a professor at the Icahn School of Medicine at Mount Sinai, during a call to the Infectious Diseases Society of America on Friday.

“The question that arises is whether this is something that is unique to Covid itself – and it is the Covid virus that is causing these symptoms – or whether this could be part of a general post-viral syndrome,” Navis said, adding, that medical experts see similar long-term symptoms after other viral infections.

Another study, published in the medical journal The Lancet in early January, looked at 1,733 patients discharged from a hospital in Wuhan, China, between January and May last year. Of these patients, 76% reported at least one symptom six months after their first illness. The proportion was higher among women.

“We found that fatigue or muscle weakness, sleep disorders, and anxiety or depression were common even 6 months after symptoms appeared,” the researchers wrote in the study.

They found that symptoms reported months after the Covid-19 diagnosis was consistent with data previously found in follow-up studies of Severe Acute Respiratory Syndrome (SARS), a coronavirus.

Post-Covid clinics are going online

Some large medical centers are currently setting up post-Covid clinics to care for patients with persistent symptoms. Navis said her clinic on Mount Sinai, New York treated a “fairly even” distribution of men and women with persistent illness, and the average age of patients was 40 years.

Dr. Kathleen Bell, a professor at the University of Texas’ Southwestern Medical Center, said her hospital’s long-term Covid-19 clinic began last April when a wave of infections hit Italy and New York at the start of the pandemic.

Bell said on the Infectious Diseases Society of America conference call on Friday that a number of professionals are required to staff the clinics because symptoms are uneven, including experts who can treat muscle weakness, heart-related disorders, and cognitive problems in the insane and health Problems after their diagnosis.

“It forces all of us, in many ways, to come together and make sure we have open lines of communication to address all of these issues for patients,” said Bell.

Bell added that the Centers for Disease Control and Prevention held a phone call in January with long Covid centers across the country to discuss their model for treating patients.

“I think the CDC is now trying to bring centers together and get some firmer guidelines on it, which is very exciting,” said Bell.

– CNBC’s Sam Meredith contributed to this report.

Categories
Health

Tilray inventory soars, firm to offer medical hashish in French examine

A worker inspects cannabis plants in the grow room of Aphria Inc.’s diamond factory in Leamington, Ontario, Canada on Wednesday, January 13, 2021. Tilray Inc. and Aphria Inc. have agreed to combine their activities to form a new giant in the fast growing cannabis industry.

Annie Sakkab | Bloomberg | Getty Images

Shares in Canadian cannabis company Tilray rose nearly 10% Tuesday after it was announced that the French government had been using it to provide cannabis for medical experiments.

The French National Agency for the Safety of Medicines and Health Products will start the 18- to 24-month study in the first quarter. Tilray’s products will treat patients with neuropathic pain, epilepsy and multiple sclerosis that are not relieved by existing treatments.

Tilray will export the medical cannabis products from its facility in Cantanhede, Portugal, which serves as the central research and development center for medical cannabis.

“Today’s announcement marks another milestone for Tilray as we expand our operations in Europe,” said Brendan Kennedy, Tilray chief executive.

Tilray stock is down about 2% in the past 12 months, increasing its market value to $ 2.53 billion.